Equities analysts predict that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will post earnings per share of ($0.78) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Cellular Biomedicine Group’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.91). Cellular Biomedicine Group reported earnings of ($0.45) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 73.3%. The firm is scheduled to issue its next earnings results on Tuesday, February 18th.
On average, analysts expect that Cellular Biomedicine Group will report full year earnings of ($2.69) per share for the current financial year, with EPS estimates ranging from ($2.87) to ($2.44). For the next fiscal year, analysts forecast that the company will post earnings of ($2.45) per share, with EPS estimates ranging from ($2.80) to ($1.96). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Cellular Biomedicine Group.
A number of equities research analysts have recently issued reports on the company. BTIG Research assumed coverage on Cellular Biomedicine Group in a report on Tuesday, September 17th. They set a “buy” rating and a $19.00 price objective for the company. BidaskClub upgraded Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Finally, ValuEngine upgraded Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Friday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Cellular Biomedicine Group presently has a consensus rating of “Buy” and a consensus target price of $24.00.
Several hedge funds have recently modified their holdings of CBMG. Charles Schwab Investment Management Inc. lifted its stake in Cellular Biomedicine Group by 13.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 28,526 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 3,323 shares during the last quarter. Northern Trust Corp increased its holdings in Cellular Biomedicine Group by 5.0% in the second quarter. Northern Trust Corp now owns 170,273 shares of the biotechnology company’s stock valued at $2,815,000 after purchasing an additional 8,101 shares during the period. Platinum Investment Management Ltd. increased its holdings in Cellular Biomedicine Group by 2.9% in the second quarter. Platinum Investment Management Ltd. now owns 672,885 shares of the biotechnology company’s stock valued at $11,123,000 after purchasing an additional 19,170 shares during the period. Nikko Asset Management Americas Inc. increased its holdings in Cellular Biomedicine Group by 4.8% in the third quarter. Nikko Asset Management Americas Inc. now owns 557,752 shares of the biotechnology company’s stock valued at $8,288,000 after purchasing an additional 25,434 shares during the period. Finally, ARK Investment Management LLC increased its holdings in Cellular Biomedicine Group by 10.0% in the second quarter. ARK Investment Management LLC now owns 314,378 shares of the biotechnology company’s stock valued at $5,197,000 after purchasing an additional 28,616 shares during the period. Institutional investors and hedge funds own 20.49% of the company’s stock.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
Recommended Story: What is meant by buying and selling pressure?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.